Plasma levels of IL-1β and IL-37 in patients with severe haemophilia

Pei-Chin Lin1,2,3,4, Shyh-Shin Chiou1,2,3,4, Wan-Yi Hsu1,2,4, Yu-Mei Liao1,2,4, Shih-Pien Tsai4,5, Hsiu-Lan Su5, Ping-Tao Lu4 and Yu-Hsin Tseng1

Abstract

Objective: Haemophilia A and B are disorders caused by the lack of clotting factors VIII and IX, respectively. Repeated bleeding into the same joint leads to haemophilic arthropathy (HA). Interleukin (IL)-1β is responsible for the pro-inflammatory response and IL-37 is induced by IL-1β stimuli to have an anti-inflammatory response and prevent uncontrolled inflammation and tissue damage. Our objective was to investigate plasma levels of IL-1β and IL-37 in patients with severe haemophilia with different severities of HA.

Methods: Peripheral blood samples were collected from 14 patients with severe haemophilia A and 6 with severe haemophilia B, and 18 healthy individuals. Plasma levels of IL-1β and IL-37 were detected by immunoassay, and severity of HA was evaluated using the Pettersson scoring system. Plasma levels of IL-1β and IL-37 were analysed in patients with severe haemophilia grouped by Pettersson score and in healthy individuals.

Results: Plasma levels of IL-1β and IL-37 were significantly higher in patients with severe haemophilia compared with healthy individuals and significantly lower in those with moderate to severe HA than in those with no or mild HA.

Conclusions: Plasma levels of IL-1β and IL-37 may be useful to track HA progression in patients with severe haemophilia.
Keywords
Haemophilia, haemophilic arthropathy, Pettersson score, interleukin-1β, interleukin-37, cytokine

Date received: 21 January 2020; accepted: 15 June 2020

Introduction

Haemophilia is an X-linked bleeding disorder in which the blood clotting process is slowed. Haemophilia A and B are caused by deficiency of clotting factors VIII and IX, respectively. Based on the plasma levels of clotting factors, haemophilia can be classified as severe (factor levels <1%), moderate (factor levels 1% to 5%), or mild (factor levels >5% to 30%). Haemophilic arthropathy (HA) is the most typical manifestation caused by repeated bleeds in patients with haemophilia. Repeated bleeding into the same joint causes pain, progressive rigidity, marked limitation of motion, muscle wasting, and osteoporosis, leading to chronic proliferative synovitis, cartilage degeneration, bone degeneration, and eventually impaired joint function. The treatment of acute haemarthrosis is limited to early replacement of clotting factor concentrate combined with rest until the pain subsides. No specific therapies have been developed for preventing damage caused by blood already present in the joints.

In 2015, Van Vulpen et al. demonstrated that interleukin (IL)-1β is the main mediator of cartilage damage. Blocking IL-1β can prevent chondrocyte apoptosis and cartilage damage. These findings indicate new possibilities for the prevention of blood-induced joint damage in haemophilia. In addition, several IL-1β blockers, including anakinra (a recombinant IL-1 receptor antagonist), rilonacept (an anti-IL-1β dimeric glycoprotein), and canakinumab (a recombinant human anti-IL-1β monoclonal antibody), have been clinically used to treat arthritis caused by gout. IL-1β belongs to the IL-1 family (IL-1F), which has 11 members and 10 receptors. However, the expression levels of members of this family in haemophilia have been rarely investigated.

IL-37 is an IL-1F cytokine discovered by Kumar et al. in 2000. The main function of IL-37 is anti-inflammatory and IL-37 has been found to play an important role in a variety of inflammatory diseases, autoimmune diseases, and tumours. IL-37 is not constitutively expressed in blood monocytes of healthy individuals but is induced by pro-inflammatory stimuli, such as IL-1β; the activation of IL-37 is a protective mechanism to prevent uncontrolled inflammation and excessive tissue damage.

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disease characterized mainly by joint inflammation and destruction. A variety of cytokines are involved in the pathogenesis of RA, including IL-37. Serum levels of IL-37 are significantly higher in patients with RA than in healthy individuals and are closely related to disease activity (C-reactive protein, erythrocyte sedimentation rate, and Disease Activity Score-28). After treatment with disease-modifying antirheumatic drugs, IL-37 levels are decreased in drug-susceptible patients. In vitro experiments have shown that IL-37 significantly suppresses the expression of IL-1β. An elevated IL-37 level has also been observed in patients with erosive inflammatory osteoarthritis (OA) and is positively correlated with disease activity and pro-inflammatory cytokines such as IL-1β, tumour necrosis factor (TNF)-α,
and IL-6 in peripheral blood mononuclear cells and synovial cells. In addition, recombinant IL-37 can suppress expression of pro-inflammatory cytokines. Intra-articular injections of recombinant IL-37 or adenovirus encoding human IL-37 in mice with collagen-induced or streptococcal cell wall-induced arthritis have been shown to ameliorate arthritic symptoms.

HA has the inflammatory characteristics of RA and the degenerative features of OA. In RA and OA, many cellular constituents and plasma constituents, including cytokines, have been detected and considered potentially responsible for HA. However, the expression level of IL-37 in HA has been not investigated. In this study, we grouped patients with severe haemophilia according to severity of HA. Then, we detected and compared plasma levels of IL-1β and IL-37 between healthy individuals, patients with severe haemophilia, and groups of patients with different severities of HA.

Materials and Methods

Ethical approval

This study was approved by the Institutional Review Board of Kaohsiung Medical University Hospital (KMUHIRB-SV(II)-20150094). Written informed consent was obtained from each participant.

Patient enrolment

Peripheral blood samples were collected from patients with severe haemophilia A (n = 14), aged 10 to 54 (29.27 ± 3.43) years or with severe haemophilia B (n = 6), aged 7 to 37 (23.13 ± 4.18) years. Of these, two patients received primary prophylaxis that started before the age of 3 years; two patients had on-demand treatment followed by secondary prophylaxis since the age of 14 and 26 years; and the others had on-demand treatment. The severity of HA was evaluated using the Pettersson scoring system. Ankles, knees, and elbows are hinge joints, which are the major joints affected in HA. Therefore, we used Pettersson scores of these six joints (bilateral elbows, bilateral ankles, and bilateral knees) to classify the severity of HA in our patients. The Pettersson scoring system used the following items to evaluate HA: orthopaedic changes in osteoporosis, enlarged epiphysis, irregular subchondral surface, narrowing of joint space, subchondral cyst formation, erosion of joint margins, gross incongruence of articulating bone ends, and joint deformity. Each joint was scored between 0 and 13 points, where score 0 represents no arthropathy, score 1 to 4 represents mild arthropathy, and score 5 to 13 represents moderate to severe arthropathy. Therefore, we use a score of 5 to divide patients into two groups. Patients with a Pettersson score <5 for each joint were grouped into group A, whereas patients with a Pettersson score ≥5 for any joint were grouped into group B. Our participants did not have a history of hepatitis B virus infection or hypertension. Although 10 of 20 patients had been infected with hepatitis C virus (HCV), they were treated and negative for HCV RNA in their blood samples when they were enrolled in this study. In addition, healthy volunteers (n = 18) with no history of arthritis, aged 23 to 54 (33.88 ± 1.95) years, were randomly enrolled as controls.

Immunoassays

Venous peripheral blood of patients with haemophilia and healthy individuals was collected using ethylenediaminetetraacetic acid as the anticoagulant agent. Plasma was obtained through centrifugation at 1000 × g at 4°C for 10 minutes and stored at −80°C until use. Plasma levels of IL-1β
and IL-37 were determined using the ProCartaPlex immunoassay (PPX-05-MXYGRG6; Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer’s instructions. The sensitivity limit was 1.99 pg/mL for IL-1β and 4.22 pg/mL for IL-37. Frozen samples were thawed on ice and mixed well by vortexing, followed by centrifugation at 10,000 × g for 10 minutes. Then, 25 μL of 1× Universal Assay Buffer with magnetic beads was added to dedicated wells, followed by 25 μL of standard or sample, and the plates were incubated with shaking at room temperature for 60 to 120 minutes. For the wash steps, 150 μL of wash buffer was added to each well and incubated for 30 s. The wash buffer was removed from the wells by quickly inverting the plate and blotting it on absorbent paper to remove any residual solution. Then, 25 μL of detection antibody solution was added to each well and incubated with shaking at room temperature for 30 minutes. A wash step was performed to remove excess antibody and 50 μL of streptavidin-phycoerythrin (PE) was added to each well and incubated with shaking at room temperature for 30 minutes. A wash step was performed to remove excess streptavidin-PE. Finally, 120 μL of reading buffer was added to the mixture and shaken at room temperature for 5 minutes before the data were acquired on a Luminex 200 system multiplex analyser (Luminex Corp., Austin, TX, USA).

Statistical analysis

Statistical analyses were performed using GraphPad Prism Version 5 (GraphPad Prism Software, Los Angeles, CA, USA). Measurement data are expressed as mean ± standard error of the mean (SEM). The unpaired Student’s t test was used to determine intergroup differences, and linear regression was used to determine the relationship between two continuous variables. p < 0.05 was considered statistically significant.

Results

IL-1β and IL-37 plasma levels in patients with severe haemophilia and healthy individuals

Plasma levels of IL-1β and IL-37 were compared between patients with severe haemophilia and healthy individuals. The IL-1β and IL-37 levels were significantly higher (p < 0.0001) in patients with severe haemophilia than in the healthy individuals (Figure 1).

Figure 1. Analysis of plasma levels of interleukin (IL)-1β and IL-37 between patients with severe haemophilia and healthy individuals. IL-1β and IL-37 plasma levels were significantly higher in patients with severe haemophilia (n = 20) than in healthy individuals (n = 18). *p < 0.05.
IL-1β and IL-37 plasma levels in patients grouped by Pettersson scores

The age and Pettersson scores of six index joints per patient are listed in Table 1. Patients were grouped into Pettersson group A (no arthropathy or mild arthropathy) and Pettersson group B (moderate to severe arthropathy) as described above. In total, 120 joints of 20 patients were evaluated. The number of affected joints per patient ranged from 0 to 6. In group A, five of eight patients had no affected joint, two patients had two affected joints, and one patient had one affected joint. In group B, two patients had six affected joints, two patients had five affected joints, two patients had four affected joints, five patients had three affected joints, and one patient had one affected joint. The average numbers of affected joints per patient of group A and B were 0.625 and 3.83, respectively. Our results showed that the IL-1β plasma levels in group A (p = 0.0004) or group B (p = 0.0007) patients were significantly higher than those in healthy individuals. The plasma levels of IL-37 in group A (p < 0.0001) or group B (p = 0.0108) patients were significantly higher than those in healthy individuals. In addition, plasma levels of IL-1β (p = 0.0038) and IL-37 (p = 0.0105) were significantly lower in group B patients than in group A patients (Figure 2).

Correlation between cytokine levels and Pettersson scores

We analysed correlations between cytokine levels and the total Pettersson scores of six

Table 1. Patients grouped according to Pettersson score (indicating severity of haemophilic arthropathy) in six joints.

| Haemophilia type | Age (years) | Pettersson score | Sum | Group |
|------------------|-------------|------------------|-----|-------|
|                  |             | Right elbow      | Left elbow | Right knee | Left knee | Right ankle | Left ankle |       |
| A                | 20          | 0                | 0               | 0           | 0         | 0           | 0         | A     |
| B                | 23          | 0                | 0               | 0           | 0         | 0           | 0         | A     |
| B                | 17          | 0                | 0               | 0           | 0         | 0           | 0         | A     |
| B                | 7           | 0                | 0               | 0           | 0         | 0           | 0         | A     |
| A                | 21          | 0                | 0               | 0           | 2         | 0           | 2         | A     |
| A                | 11          | 0                | 0               | 0           | 3         | 3           | 6         | A     |
| A                | 11          | 0                | 0               | 0           | 0         | 0           | 0         | A     |
| A                | 19          | 0                | 0               | 1           | 1         | 0           | 2         | A     |
| B                | 38          | 0                | 0               | 0           | 11        | 0           | 11        | B     |
| A                | 28          | 0                | 0               | 2           | 0         | 12          | 7         | 21 B  |
| A                | 29          | 2                | 2               | 0           | 0         | 7           | 7         | 18 B  |
| B                | 26          | 5                | 5               | 5           | 0         | 0           | 0         | 15 B  |
| A                | 26          | 6                | 6               | 5           | 5         | 4           | 0         | 26 B  |
| B                | 28          | 6                | 0               | 0           | 6         | 6           | 18        | B     |
| A                | 31          | 7                | 7               | 0           | 0         | 7           | 0         | 21 B  |
| A                | 54          | 9                | 13              | 9           | 13        | 0           | 7         | 51 B  |
| A                | 35          | 10               | 10              | 0           | 0         | 10          | 10        | 40 B  |
| A                | 44          | 11               | 11              | 12          | 12        | 13          | 13        | 72 B  |
| A                | 35          | 6                | 6               | 6           | 6         | 6           | 6         | 36 B  |
| A                | 45          | 11               | 12              | 0           | 12        | 0           | 0         | 35 B  |

Pettersson score A: patients with a score < 5 for each joint; Pettersson score B: patients with a score ≥ 5 for any joint.
joints. There was a negative correlation between IL-1β ($p = 0.0294$) and IL-37 ($p = 0.0272$) plasma levels and the total Pettersson scores and a positive correlation ($p < 0.0001$) between IL-1β and IL-37 plasma levels (Figure 3). 

**Discussion**

HA is considered to result from the direct effects of blood components on cartilage and indirectly from synovial inflammation. Pro-inflammatory cytokines from blood induce chondrocyte apoptosis and produce cartilage-degrading proteases. Recombinant human IL-1β monoclonal antibodies or IL-1 receptor antagonists protect cartilage from blood-induced damage. Although more in vivo studies and clinical trials are required, IL-1β has been shown to play a critical role in HA.

IL-37 is regulated by inflammatory stimuli and pro-cytokines through various signal transduction pathways. IL-37 is expressed and exerts anti-inflammatory...
effects in various diseases, including RA, OA, melanoma, morbid obesity, contact hypersensitivity, atopic dermatitis, liver inflammatory injury, and systemic lupus erythematosus. \(18,20,27\) IL-37 regulates the inflammatory response mainly by inhibiting the expression, production, and functionality of pro-inflammatory cytokines such as IL-1\(\alpha\), IL-1\(\beta\), IL-6, IL-12, and TNF-\(\alpha\). \(18\) The silencing of IL-37 enhances cytokine production associated with pro-inflammatory stimuli. \(18,22\) An elevated IL-37 level has also been observed in patients with RA and erosive inflammatory OA and is positively correlated with disease activity. \(14,16,20\)

In this study, plasma levels of IL-1\(\beta\) and IL-37 were significantly higher in patients with severe haemophilia than in healthy individuals. The IL-37 plasma level was similar to the IL-1\(\beta\) expression profile and there was a positive correlation between IL-1\(\beta\) and IL-37 plasma levels in patients with severe haemophilia. This result may represent secretion of IL-37 to fight the pro-inflammatory response caused by IL-1\(\beta\). In addition, IL-1\(\beta\) and IL-37 plasma levels were significantly lower in haemophilia patients with moderate to severe HA (group B, comprising those with Pettersson score \(\geq 5\) for any joint) than in those with no or mild HA (group A, comprising those with Pettersson score \(< 5\) for all joints). The clinical stages in the developmental process of HA are recurrent bleeding, panarthritis, and fibrosis. \(28\) Bleeding and the severe inflammatory response usually occur at an early stage; bleeding is an uncommon manifestation in the late stage. \(28\) This may be why IL-1\(\beta\) and IL-37 plasma levels were lower in group B patients (closer to the fibrosis stage) than in group A patients (in the recurrent bleeding and panarthritis stages).

Patients in Pettersson group A were younger than patients in Pettersson group B (Table 1); however, we found no correlation between age and IL-1\(\beta\) \((p = 0.3774)\) or IL-37 \((p = 0.9353)\) plasma level in healthy individuals (data not shown). Therefore, we can exclude an effect of age on changes in IL-1\(\beta\) and IL-37 levels. HA is clinically less severe in patients with haemophilia B than in patients with haemophilia A. \(30\) However, we collected samples from patients with severe haemophilia A and severe haemophilia B in this study. In addition, our patients were grouped according to Pettersson score (the severity indicator of HA), which excludes the interference of haemophilia types. Although more research data are needed, IL-1\(\beta\) and IL-37 may be potential predictors of HA progression; that is, levels of IL-1\(\beta\) and IL-37 increase in the recurrent bleeding and panarthritis stages and then begin to decrease from the highest point, which may indicate that HA is progressing to the fibrosis stage.

**Conclusions**

Our results showed that plasma levels of IL-1\(\beta\) and IL-37 were significantly higher in patients with severe haemophilia than in healthy individuals and significantly lower in patients with moderate to severe HA than in those with no or mild HA. Continuous tracking of IL-1\(\beta\) and IL-37 plasma levels in patients with severe haemophilia could enable prediction of HA progression. Whether recombinant IL-37 can inhibit inflammation by inhibiting IL-1\(\beta\) signalling and has potential as a therapeutic agent for HA is worthy of further research.

**Declaration of conflicting interest**

The authors declare that there is no conflict of interest.

**Funding**

This study was supported by a grant from Kaohsiung Medical University Hospital (KMUH105-5T09).

**ORCID iD**

Yu-Hsin Tseng [https://orcid.org/0000-0002-2558-2209](https://orcid.org/0000-0002-2558-2209)
References

1. Tseng YH, Chiou SS, Zeng YS, et al. Soluble vascular cell adhesion molecular-1 is a potential biological indicator of haemophilic arthropathy. *Medicine (Baltimore)* 2016; 95: e5384.

2. Scott MJ, Xiang H, Hart DP, et al. Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: the THUNDER study. *Haemophilia* 2019; 25: 205–212.

3. Hua B, Olsen EHN, Sun S, et al. Serological biomarkers detect active joint destruction and inflammation in patients with haemophilic arthropathy. *Haemophilia* 2017; 23: e294–e300.

4. Garagiola I, Palla R and Peyvandi F. Risk factors for inhibitor development in severe hemophilia A. *Thromb Res* 2018; 168: 20–27.

5. Onasoga-Jarvis AA, Leiderman K, Fogelson AL, et al. The effect of factor VIII deficiencies and replacement and bypass therapies on thrombus formation under venous flow conditions in microfluidic and computational models. *PLoS One* 2013; 8: e78732.

6. Teyssler P, Kolostova K and Bobek V. Assessment of pain threshold in haemophilic patients. *Haemophilia* 2014; 20: 207–211.

7. Wojdasiewicz P, Poniatowski LA, Nauman P, et al. Cytokines in the pathogenesis of hemophilic arthropathy. *Cytokine Growth Factor Rev* 2018; 39: 71–91.

8. Aronstam A, Rainsford SG and Painter MJ. Patterns of bleeding in adolescents with severe haemophilia A. *Br Med J* 1979; 1: 469–470.

9. Srivastava A. Inflammation is key to hemophilic arthropathy. *Blood* 2015; 126: 2175–2176.

10. Van Vulpen LF, Schutgens RE, Coeleveld K, et al. IL-1beta, in contrast to TNFalpha, is pivotal in blood-induced cartilage damage and is a potential target for therapy. *Blood* 2015; 126: 2239–2246.

11. Schlesinger N. Anti-interleukin-1 therapy in the management of gout. *Curr Rheumatol Rep* 2014; 16: 398.

12. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. *Immunol Rev* 2018; 281: 8–27.

13. Kumar S, McDonnell PC, Lehr R, et al. Identification and initial characterization of four novel members of the interleukin-1 family. *J Biol Chem* 2000; 275: 10308–10314.

14. Jia H, Liu J and Han B. Reviews of interleukin-37: functions, receptors, and roles in diseases. *BioMed Res Int* 2018; 2018: 3058640.

15. Cavalli G and Dinarello CA. Suppression of inflammation and acquired immunity by IL-37. *Immunol Rev* 2018; 281: 179–190.

16. Yang L, Zhang J, Tao J, et al. Elevated serum levels of interleukin-37 are associated with inflammatory cytokines and disease activity in rheumatoid arthritis. *APMIS* 2015; 123: 1025–1031.

17. Zhao PW, Jiang WG, Wang L, et al. Plasma levels of IL-37 and correlation with TNF-alpha, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis. *PLoS One* 2014; 9: e95346.

18. Xia T, Zheng XF, Qian BH, et al. Plasma interleukin-37 is elevated in patients with rheumatoid arthritis: its correlation with disease activity and Th1/Th2/Th17-related cytokines. *Dis Markers* 2015; 2015: 795043.

19. Ye L, Jiang B, Deng J, et al. IL-37 alleviates rheumatoid arthritis by suppressing IL-17 and IL-17-triggering cytokine production and limiting Th17 cell proliferation. *J Immunol* 2015; 194: 5110–5119.

20. Ding L, Hong X, Sun B, et al. IL-37 is associated with osteoarthritis disease activity and suppresses proinflammatory cytokines production in synovial cells. *Sci Rep* 2017; 7: 11601.

21. Routet MA, Nerviani A and Pitzalis C. IL-36, IL-37, and IL-38 cytokines in skin and joint inflammation: a comprehensive review of their therapeutic potential. *Int J Mol Sci* 2019; 20: 1257.

22. Cavalli G, Koenders M, Kalabokis V, et al. Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. *Rheumatology (Oxford)* 2017; 56: 2256.

23. Nacca CR, Harris AP and Tuttle JR. Hemophilic arthropathy. *Orthopedics* 2017; 40: e940–e946.

24. Stephensen D, Tait RC, Brodie N, et al. Changing patterns of bleeding in patients with severe haemophilia A. *Haemophilia* 2009; 15: 1210–1214.
25. Chang CY, Li TY, Cheng SN, et al. Prevalence and severity by age and other clinical correlates of haemophilic arthropathy of the elbow, knee and ankle among Taiwanese patients with haemophilia. *Haemophilia* 2017; 23: 284–291.

26. Hanley J, McKernan A, Creagh MD, et al. Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: a United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) guideline. *Haemophilia* 2017; 23: 511–520.

27. Wang L, Quan Y, Yue Y, et al. Interleukin-37: a crucial cytokine with multiple roles in disease and potentially clinical therapy. *Oncol Lett* 2018; 15: 4711–4719.

28. Musculoskeletal Complications of Hemophilia: The Joint [homepage on the Internet], 1997. Treatment of Hemophilia Monographs.

29. Franchini M and Mannucci PM. Haemophilia B is clinically less severe than haemophilia A: further evidence. *Blood Transfus* 2018; 16: 121–122.